by EpicentRx | Sep 18, 2015 | Conferences
September 2015, Washington, D.C. Invited Presentation: Restoring efficacy of immunotherapy treatments in oncology with radical oxygen and nitrogen based epigenetic drugs
by EpicentRx | Sep 18, 2015 | Conferences
September 2015, Atlanta, Georgia Abstract: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing Phase 2 colorectal cancer study, “ROCKET”
by EpicentRx | May 18, 2015 | Conferences
May 2015, Toronto, Canada Abstract: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI in preclinical tumor models
by EpicentRx | Apr 18, 2015 | Conferences
April 2015, Philadelphia, Pennsylvania Abstract: Early results from a phase 2 study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer
by EpicentRx | Mar 18, 2015 | Conferences
March 2015, Paris, France Abstract: Early results: “ROCKET” a phase II study of RRx-001, a novel triple epigenetic inhibitor, resensitization to irinotecan in colorectal cancer
